Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Other Events

Item8.01

OnJune 21, 2017, Five Prime Therapeutics, Inc. (the
Company)issued a press release announcingthat Lewis T. Williams,
M.D., Ph.D. plans to transition from his position as President,
Chief Executive Officer and Chairman of the Board of Directors
(the Board) to the role of Executive Chairman of the Board in
2018.The Board will conduct a comprehensive search for a
candidate to fill the position of Chief Executive Officer, and
Dr.Williams will remain in his current position until the new
Chief Executive Officer has been appointed.

A copy of the press release is filed herewith as Exhibit 99.1 and
the information contained therein is incorporated by reference
into this Current Report on Form 8-K.

(d) Exhibits.

2

FIVE PRIME THERAPEUTICS INC Exhibit
EX-99.1 2 d426390dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 SOUTH SAN FRANCISCO,…
To view the full exhibit click here
About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)

Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).